ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

In Brief: French 10 Years Behind In Treatment Techniques, Rauscher Tells Premier; European Interest Grows

September 26, 1975

Clinical Trials Approved By NCI CTEP Last Month

May 27, 2011

DCPC Board Approves Concepts Of Six New RFAs Totaling $9.3 Million A Year

May 11, 1984

Researchers Link Cancer Risk And DMPA Birth Control Use

April 27, 2012

In Congress: NCI Apologizes For Delay In Report On Radioactive Fallout

September 18, 1998

Letter; ASSIST Prevents Cancer, Should Remain in NCI Portfolio

July 4, 1997